Patents by Inventor Volker Sandig

Volker Sandig has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • USE OF A BIRNAVIRUS ALONE OR IN COMBIMATION THERAPY FOR THE TREATMENT OF A DISEASE CAUSED BY A NIDOVIRUS
    Publication number: 20240024390
    Abstract: The present invention relates to a birnavirus for use in the treatment of a disease caused by a nidovirus. Further, the present invention relates to a combination comprising at least one birnavirus and at least one further active agent for use in the treatment of a disease caused by a nidovirus. Furthermore, the present invention relates to a pharmaceutical composition comprising the birnavirus or the combination for use in the treatment of a disease caused by a nidovirus.
    Type: Application
    Filed: December 21, 2020
    Publication date: January 25, 2024
    Inventors: Imre Kovesdi, Tibor Bakacs, Volker Sandig, Shimon Slavin, Deborah Horn, Alexander Karlas, Sven Krugener
  • HYPERACTIVE TRANSPOSONS AND TRANSPOSASES
    Publication number: 20230257778
    Abstract: The present invention relates to a polypeptide comprising a piggyBac transposase or a fragment or a derivative thereof having transposase function comprising at least one amino acid substitution. Further, the present invention relates to a transposable element comprising a piggyBac or piggyBac-like left repeat sequence and left internal repeat sequence, wherein the left internal repeat sequence comprises at least one nucleotide modification. Furthermore, the present invention relates to a kit comprising the above transposase and/or transposable element. In addition, the present invention relates to a targeting system comprising the above transposase and/or transposable element.
    Type: Application
    Filed: July 17, 2020
    Publication date: August 17, 2023
    Inventors: VOLKER SANDIG, Sven Krügener, Thomas Rose
  • Method For Purifying An Enveloped Virus
    Publication number: 20220267738
    Abstract: The present invention relates to a method for purifying an enveloped virus. The present invention further relates to an enveloped virus or a plurality of enveloped viruses obtainable by said method.
    Type: Application
    Filed: June 27, 2019
    Publication date: August 25, 2022
    Applicant: ProBioGen AG
    Inventors: Volker SANDIG, Michael MÜHLE, Sven KRÜGENER
  • TRANSPOSASE WITH ENHANCED INSERTION SITE SELECTION PROPERTIES
    Publication number: 20220090142
    Abstract: The present invention relates to a polypeptide comprising a transposase and at least one heterologous chromatin reader element (CRE). Further, the present invention relates to a polynucleotide encoding the polypeptide. Furthermore, the present invention relates to a vector comprising the polynucleotide. In addition, the present invention relates to a kit comprising a transposase and at least one heterologous chromatin reader element (CRE).
    Type: Application
    Filed: February 13, 2019
    Publication date: March 24, 2022
    Inventors: Sven Krügener, Thomas Rose, Volker Sandig, Karsten Winkler
  • Vaccinia virus vectors related to MVA with extensive genomic symmetries
    Patent number: 11104884
    Abstract: The present invention relates to a novel Modified Vaccinia Ankara (MVA) related virus. The present invention also relates to a method for culturing said MVA related virus and to a method for producing said MVA related virus. Further, the present invention relates to a pharmaceutical composition comprising said MVA related virus and one or more pharmaceutical acceptable excipient(s), diluent(s), and/or carrier(s). Furthermore, the present invention relates to a vaccine comprising said MVA related virus. In addition, the present invention relates to said MVA related virus for use in medicine.
    Type: Grant
    Filed: February 23, 2017
    Date of Patent: August 31, 2021
    Assignee: Probiogen AB
    Inventors: Ingo Jordan, Volker Sandig
  • Porcine cell line for virus production
    Patent number: 11060069
    Abstract: The present invention relates to a continuous porcine cell line that is capable of proliferating in medium free of animal-derived components. Further, the present invention relates to a method for producing a virus using said cell line and a virus obtainable by said method. Furthermore, the present invention relates to a method for accumulating a virus from an environmental sample using said cell line and a virus obtainable by said method.
    Type: Grant
    Filed: November 9, 2016
    Date of Patent: July 13, 2021
    Assignee: Probiogen AB
    Inventors: Ingo Jordan, Volker Sandig, Deborah Horn, Katrin John
  • NOVEL VACCINIA VIRUS VECTORS RELATED TO MVA WITH EXTENSIVE GENOMIC SYMMETRIES
    Publication number: 20190367887
    Abstract: The present invention relates to a novel Modified Vaccinia Ankara (MVA) related virus. The present invention also relates to a method for culturing said MVA related virus and to a method for producing said MVA related virus. Further, the present invention relates to a pharmaceutical composition comprising said MVA related virus and one or more pharmaceutical acceptable excipient(s), diluent(s), and/or carrier(s). Furthermore, the present invention relates to a vaccine comprising said MVA related virus. In addition, the present invention relates to said MVA related virus for use in medicine.
    Type: Application
    Filed: February 23, 2017
    Publication date: December 5, 2019
    Inventors: Ingo Jordan, Volker Sandig
  • NOVEL PORCINE CELL LINE FOR VIRUS PRODUCTION
    Publication number: 20190300863
    Abstract: The present invention relates to a continuous porcine cell line that is capable of proliferating in medium free of animal-derived components. Further, the present invention relates to a method for producing a virus using said cell line and a virus obtainable by said method. Furthermore, the present invention relates to a method for accumulating a virus from an environmental sample using said cell line and a virus obtainable by said method.
    Type: Application
    Filed: November 9, 2016
    Publication date: October 3, 2019
    Inventors: Ingo Jordan, Volker Sandig, Deborah Horn, Katrin John
  • Methods for preparation of fucose-linked site specific conjugates of proteins with toxins, adjuvants, detection labels and pharmacokinetic half life extenders
    Patent number: 9765158
    Abstract: The present invention relates to eukaryotic cells for producing molecules having an atypical fucose analog on their glycomoieties and/or amino acids. It also relates to methods for producing molecules having an atypical fucose analog on their glycomoieties and/or amino acids and to molecules obtainable by said methods. It further relates to methods for producing conjugates comprising molecules having an atypical fucose analog on their glycomoieties and/or amino acids and pharmaceutical active compounds and to conjugates obtainable by said methods. In addition, the present invention relates to specific conjugates.
    Type: Grant
    Filed: May 31, 2012
    Date of Patent: September 19, 2017
    Assignee: Probiogen AG
    Inventors: Hans Henning Von Horsten, Volker Sandig, Ingo Jordan, Karsten Winkler
  • MVA virus and uses thereof
    Patent number: 9732325
    Abstract: The present invention relates to a novel Modified Vaccinia Ankara (MVA) virus. The present invention also relates to a method for culturing said MVA virus and to a method for producing said MVA virus. Further, the present invention relates to a pharmaceutical composition comprising said MVA virus and one or more pharmaceutical acceptable excipient(s), diluent(s), and/or carrier(s). Furthermore, the present invention relates to a vaccine comprising said MVA virus. In addition, the present invention relates to said MVA virus for use in medicine.
    Type: Grant
    Filed: September 28, 2012
    Date of Patent: August 15, 2017
    Assignee: PROBIOGEN AG
    Inventors: Ingo Jordan, Volker Sandig
  • Novel MVA Virus and Uses Thereof
    Publication number: 20150299666
    Abstract: The present invention relates to a novel Modified Vaccinia Ankara (MVA) virus. The present invention also relates to a method for culturing said MVA virus and to a method for producing said MVA virus. Further, the present invention relates to a pharmaceutical composition comprising said MVA virus and one or more pharmaceutical acceptable excipient(s), diluent(s), and/or carrier(s). Furthermore, the present invention relates to a vaccine comprising said MVA virus. In addition, the present invention relates to said MVA virus for use in medicine.
    Type: Application
    Filed: September 28, 2012
    Publication date: October 22, 2015
    Applicant: Probiogen AG
    Inventors: Ingo Jordan, Volker Sandig
  • Enhancement of protein production yield mediated by a fast shuttling CDC42 GTPase
    Patent number: 9163089
    Abstract: The present invention relates to a cell for producing a secreted protein comprising a polynucleotide comprising a nucleic acid sequence encoding a fast cycling cdc42 mutant and a polynucleotide comprising a nucleic acid sequence encoding a secreted protein. It also relates to a method for producing said cell and to a method for producing a secreted protein using said cell.
    Type: Grant
    Filed: May 14, 2012
    Date of Patent: October 20, 2015
    Assignee: Probiogen AG
    Inventors: Volker Sandig, Karsten Winkler, Henning Von Horsten, Thomas Rose
  • Immortalized avian cell lines for virus production
    Patent number: 8940534
    Abstract: The present invention relates to immortalized avian cell lines suitable for production of biologicals or viruses for vaccination. In particular, the cell lines are derived from primary cells which are transformed with at least two viral or cellular genes, one of which causes cell cycle progression whereas the other interferes with innate protective mechanisms of the cell induced by dysregulated replication. The invention moreover relates to the production of said immortalized cell lines and their use for producing biologicals or viruses for vaccination.
    Type: Grant
    Filed: November 3, 2004
    Date of Patent: January 27, 2015
    Assignee: Probiogen AG
    Inventors: Volker Sandig, Ingo Jordan
  • ENHANCEMENT OF PROTEIN PRODUCTION YIELD MEDIATED BY A FAST SHUTTLING CDC42 GTPASE
    Publication number: 20140377803
    Abstract: The present invention relates to a cell for producing a secreted protein comprising a polynucleotide comprising a nucleic acid sequence encoding a fast cycling cdc42 mutant and a polynucleotide comprising a nucleic acid sequence encoding a secreted protein. It also relates to a method for producing said cell and to a method for producing a secreted protein using said cell.
    Type: Application
    Filed: May 14, 2012
    Publication date: December 25, 2014
    Applicant: PROBIOGEN AG
    Inventors: Volker Sandig, Karsten Winkler, Henning Von Horsten, Thomas Rose
  • Productivity augmenting protein factor, novel cell lines and uses thereof
    Patent number: 8815540
    Abstract: The present invention provides a method for preparing a non-adenoviral target virus or target proteins utilizing a potent expression cell line having stably integrated into its genome a gene encoding a specific heterologous regulator protein.
    Type: Grant
    Filed: May 8, 2008
    Date of Patent: August 26, 2014
    Assignee: Probiogen AG
    Inventors: Volker Sandig, Ingo Jordan, Elisabeth Brundke
  • METHODS FOR PREPARATION OF FUCOSE-LINKED SITE SPECIFIC CONJUGATES OF PROTEINS WITH TOXINS, ADJUVANTS, DETECTION LABELS AND PHARMACOKINETIC HALF LIFE EXTENDERS
    Publication number: 20140221627
    Abstract: The present invention relates to eukaryotic cells for producing molecules having an atypical fucose analogue on their glycomoieties and/or amino acids. It also relates to methods for producing molecules having an atypical fucose analogue on their glycomoieties and/or amino acids and to molecules obtainable by said methods. It further relates to methods for producing conjugates comprising molecules having an atypical fucose analogue on their glycomoieties and/or amino acids and pharmaceutical active compounds and to conjugates obtainable by said methods. In addition, the present invention relates to specific conjugates.
    Type: Application
    Filed: May 31, 2012
    Publication date: August 7, 2014
    Applicant: ProBioGen AG
    Inventors: Hans Henning Von Horsten, Volker Sandig, INgo Jordan, Karsten Winkler
  • Cell line from rousettus as host cell for pathogen amplification
    Patent number: 8679839
    Abstract: The present invention relates to permanent cell lines from chiropterans suitable for amplification and production of microbial agents, preferably viruses, and its use for diagnostic or therapeutic purposes.
    Type: Grant
    Filed: March 4, 2009
    Date of Patent: March 25, 2014
    Assignee: Probiogen AG
    Inventors: Ingo Jordan, Deborah Horn, Volker Sandig
  • Process for producing molecules containing specialized glycan structures
    Patent number: 8642292
    Abstract: The present invention relates to cells for producing a molecule lacking fucose, having a reduced amount of fucose, or having other atypical sugars on its glycomoieties. It also relates to methods for producing a molecule lacking fucose, having a reduced amount of fucose, or having other atypical sugars on its glycomoieties using said cells and to molecules obtainable by said methods. The present invention further relates to molecules having an artificial glycosylation pattern.
    Type: Grant
    Filed: September 21, 2010
    Date of Patent: February 4, 2014
    Assignee: Probiogen AG
    Inventors: Volker Sandig, Hans Henning von Horsten, Christiane Ogorek
  • IMMORTALIZED AVIAN CELL LINES FOR VIRUS PRODUCTION
    Publication number: 20120288916
    Abstract: The present invention relates to immortalized avian cell lines suitable for production of biologicals or viruses for vaccination. In particular, the cell lines are derived from primary cells which are transformed with at least two viral or cellular genes, one of which causes cell cycle progression whereas the other interferes with innate protective mechanisms of the cell induced by dysregulated replication. The invention moreover relates to the production of said immortalized cell lines and their use for producing biologicals or viruses for vaccination.
    Type: Application
    Filed: July 26, 2012
    Publication date: November 15, 2012
    Applicant: PROBIOGEN AG
    Inventors: Volker Sandig, Ingo Jordan
  • AAD-1 EVENT DAS-40278-9, RELATED TRANSGENIC CORN LINES, AND EVENT-SPECIFIC IDENTIFICATION THEREOF
    Publication number: 20120214975
    Abstract: The present invention relates to cells for producing a molecule lacking fucose, having a reduced amount of fucose, or having other atypical sugars on its glycomoieties. It also relates to methods for producing a molecule lacking fucose, having a reduced amount of fucose, or having other atypical sugars on its glycomoieties using said cells and to molecules obtainable by said methods. The present invention further relates to molecules having an artificial glycosylation pattern.
    Type: Application
    Filed: September 21, 2010
    Publication date: August 23, 2012
    Inventors: Volker Sandig, Hans Henning Von Horsten, Christiane Ogorek